Elisabeth Ejerblad

1.6k total citations · 1 hit paper
23 papers, 1.1k citations indexed

About

Elisabeth Ejerblad is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Elisabeth Ejerblad has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 11 papers in Genetics and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Elisabeth Ejerblad's work include Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Elisabeth Ejerblad is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Elisabeth Ejerblad collaborates with scholars based in Sweden, United States and Denmark. Elisabeth Ejerblad's co-authors include Jon P. Fryzek, C. Michael Fored, Joseph K. McLaughlin, Per Lindblad, Olof Nyrén, Carl‐Gustaf Elinder, Paul W. Dickman, Matthew M. Zack, Lisa B. Signorello and William J. Blot and has published in prestigious journals such as New England Journal of Medicine, Blood and Journal of the American Society of Nephrology.

In The Last Decade

Elisabeth Ejerblad

22 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obesity and Risk for Chronic Renal Failure

2006 511 citations Elisabeth Ejerblad, C. Michael Fored et al. Journal of the American Society of Nephrology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elisabeth Ejerblad Sweden	10	377	202	168	160	153	23	1.1k
Michele F. Eisenga Netherlands	21	374 1.0×	291 1.4×	211 1.3×	134 0.8×	230 1.5×	89	1.5k
Szu-Chun Hung Taiwan	18	530 1.4×	221 1.1×	110 0.7×	205 1.3×	255 1.7×	30	1.3k
Angel de Francisco Spain	15	610 1.6×	500 2.5×	204 1.2×	166 1.0×	157 1.0×	19	1.7k
Kirsten L. Johansen United States	16	466 1.2×	276 1.4×	127 0.8×	175 1.1×	52 0.3×	24	1.1k
Shijun Li China	17	715 1.9×	70 0.3×	92 0.5×	166 1.0×	221 1.4×	40	1.3k
Chamberlain I. Obialo United States	16	529 1.4×	185 0.9×	43 0.3×	318 2.0×	122 0.8×	36	1.1k
Magdi Yaqoob United Kingdom	19	368 1.0×	80 0.4×	57 0.3×	80 0.5×	158 1.0×	44	1.0k
Rachel M. Holden Canada	25	1.0k 2.7×	106 0.5×	106 0.6×	435 2.7×	166 1.1×	85	2.1k
Ben Caplin United Kingdom	21	651 1.7×	81 0.4×	62 0.4×	144 0.9×	138 0.9×	49	1.2k
Marco DʼAmico Italy	13	534 1.4×	133 0.7×	84 0.5×	240 1.5×	296 1.9×	30	993

Countries citing papers authored by Elisabeth Ejerblad

Since Specialization

Citations

This map shows the geographic impact of Elisabeth Ejerblad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Ejerblad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Ejerblad more than expected).

Fields of papers citing papers by Elisabeth Ejerblad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Ejerblad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Ejerblad. The network helps show where Elisabeth Ejerblad may publish in the future.

Co-authorship network of co-authors of Elisabeth Ejerblad

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Ejerblad. A scholar is included among the top collaborators of Elisabeth Ejerblad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Ejerblad. Elisabeth Ejerblad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Creignou, Maria, Bianca Tesi, Elsa Bernard, et al.. (2025). Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study. British Journal of Haematology. 208(2). 514–523.

Nilsson, Lars, Magnus Tobiasson, Martin Jädersten, et al.. (2025). Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. Genes Chromosomes and Cancer. 64(2). e70029–e70029. 1 indexed citations

Garelius, Hege, et al.. (2023). MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients. Leukemia Research. 134. 107386–107386. 1 indexed citations

Garelius, Hege, Lars Nilsson, Caroline E. Weibull, et al.. (2023). Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective. Leukemia. 37(5). 1103–1112. 7 indexed citations

Creignou, Maria, Hege Garelius, Jörg Cammenga, et al.. (2022). Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study. Bone Marrow Transplantation. 57(4). 598–606. 4 indexed citations

Creignou, Maria, Elsa Bernard, Michael J. Crowther, et al.. (2022). Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes. Blood. 140(Supplement 1). 6968–6970. 1 indexed citations

Garelius, Hege, et al.. (2021). Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes. European Journal Of Haematology. 107(2). 219–228. 6 indexed citations

Garelius, Hege, Fryderyk Lorenz, Lars Nilsson, et al.. (2020). Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study. British Journal of Haematology. 192(3). 474–483. 9 indexed citations

Folkvaljon, Yasin, Johan Sundberg, Mats Lambe, et al.. (2018). Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register. British Journal of Haematology. 181(5). 614–627. 30 indexed citations

10.

Folkvaljon, Yasin, J. Sundberg, Mats Lambe, et al.. (2016). VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER. Haematologica. 101. 243–243. 1 indexed citations

11.

Lindgren, Marie, Jan Samuelsson, Lars Nilsson, et al.. (2014). A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy. Blood. 124(21). 1861–1861. 1 indexed citations

12.

Andréasson, Björn, Jan Samuelsson, Malin Hultcrantz, et al.. (2013). Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukemia & lymphoma. 54(10). 2226–2230. 37 indexed citations

13.

Ejerblad, Elisabeth, Hans Michael Kvasnicka, Jürgen Thiele, et al.. (2012). Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up. Hematology. 18(1). 8–13. 21 indexed citations

14.

Andersen, Christen Lykkegaard, Mary Frances McMullin, Elisabeth Ejerblad, et al.. (2012). A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood. 120(21). 803–803. 3 indexed citations

15.

Möllgård, Lars, Leonie Saft, Marianne Bach Treppendahl, et al.. (2011). Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 96(7). 963–971. 43 indexed citations

16.

Cashin, Peter, et al.. (2010). Acquired Haemophilia A and Kaposi’s Sarcoma in an HIV-Negative, HHV-8-Positive Patient: A Discussion of Mechanism and Aetiology. Acta Haematologica. 124(1). 40–43. 2 indexed citations

17.

Ejerblad, Elisabeth, C. Michael Fored, Per Lindblad, et al.. (2006). Obesity and Risk for Chronic Renal Failure. Journal of the American Society of Nephrology. 17(6). 1695–1702. 511 indexed citations breakdown →

18.

Ejerblad, Elisabeth, C. Michael Fored, Per Lindblad, et al.. (2004). Association between Smoking and Chronic Renal Failure in a Nationwide Population-Based Case-Control Study. Journal of the American Society of Nephrology. 15(8). 2178–2185. 105 indexed citations

19.

Fored, C. Michael, Gun Nise, Elisabeth Ejerblad, et al.. (2004). Absence of Association between Organic Solvent Exposure and Risk of Chronic Renal Failure. Journal of the American Society of Nephrology. 15(1). 180–186. 9 indexed citations

20.

Fored, C. Michael, Elisabeth Ejerblad, Per Lindblad, et al.. (2001). Acetaminophen, Aspirin, and Chronic Renal Failure. New England Journal of Medicine. 345(25). 1801–1808. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact